Navigation Links
Alphatec Spine Names New Chief Financial Officer
Date:6/16/2008

- Peter C. Wulff brings 25 years of financial and operational management

experience in medical device and life sciences industries

CARLSBAD, Calif., June 16 /PRNewswire/ -- Alphatec Spine announced today that Peter C. Wulff, who has more than 25 years of financial and operational management in the medical device and life sciences industries, has been named the company's new Chief Financial Officer, Vice President and Treasurer.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080616/AQM017LOGO)

Most recently, Mr. Wulff served as Executive Vice President and Chief Financial Officer for Artes Medical, Inc. (Nasdaq: ARTE), a San Diego-based medical technology company. In that position, he assisted the company in raising over $120 million in capital, including successfully managing its initial public offering (IPO) on NASDAQ. In addition, he established a responsive infrastructure to support the company's commercial development and U.S. market launch of its primary product.

Prior to joining Artes Medical, Mr. Wulff served in senior finance positions at both public and privately-held medical device and pharmaceutical companies including CryoCor, Inc., Natural Alternatives International, Inc., Epimmune Inc. and Ligand Pharmaceuticals Inc. While in these positions, in the aggregate, he helped raise more than $250 million in equity and debt financing, completed M&A transactions valued at over $270 million, directed the launch of commercial operations in Europe and orchestrated financial turnarounds and strategic collaborations.

"Peter Wulff will be a real asset for Alphatec," said Dirk Kuyper, the company's President and CEO
'/>"/>

SOURCE Alphatec Spine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. joimax(R) Revolutionizes Spine Surgery With the Launch of Newest and Fully-Endoscopic Product Innovations to Treat Spinal Canal Stenosis
2. Medtronic Spine, Formerly Kyphon Inc., to Pay U.S. $75 Million to Resolve Allegations Of Defrauding Medicare
3. Pioneer(R) Surgical Technology Introduces the BacJac(TM) Interspinous Decompression System to the European Spine Market
4. Atlas Spine Launches Stature(TM) Vertebral Body Replacement System
5. C5 Medical Werks Joins in Sponsoring SpineWeek 2008 in Geneva, Switzerland
6. The Future of Spine Care Has Just Gotten Better With the Use of SpineSix BioMotion Spinal System(TM)
7. Atlas Spine Releases Back-PAK(TM) Discectomy Set
8. Zero Patient Infections Reported as D.I.S.C. Spine and Sports Center Sets New Standard for Specialty Hospitals
9. Life Spine Expands Home Office Space, More Than Doubling Space Occupied
10. Life Spine Adds New Lynx(TM) Cross Connector to Its Lumbar Fixation Offering
11. Neurologic & Orthopedic Hospital of Chicago Ranked Among Top in Nation for Spine Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/21/2008)... -- Ikaria Holdings, Inc. today announced that it ...New Jersey Technology Council (NJTC), a 1,200-memb...support, networking opportunities, information and...rs. Ikaria earned the award based on criteria incl... provision. , , "We are delighted that the ...
(Date:11/20/2008)...ire/ -- New Jersey American Water has lifted the ...rs in the following municipalities in Middlesex, S...ounty , , , Dunellen , Ediso...South Plainfield , , , , Somerset C...idgewater , Green Brook , Hillsborou...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...re-FirstCall/ -- Duska Therapeutics,Inc., (OTC B...submitted its,pivotal Phase 3 ATPace clinical tri...ssessment (SPA) procedure with the U.S. Food and D...uring an agreement with the FDA, Duska intends to ...cebo-controlled and randomized Phase 3,clinical t...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Mindray to Attend 2007 RSNA Conference in Chicago 6781 1Mindray to Attend 2007 RSNA Conference in Chicago 6781 2Mindray to Attend 2007 RSNA Conference in Chicago 6781 3Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 1Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 1Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 3Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 1Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 2
...s TNF-alpha Production Through Inhibition,of PDE-4...ire/ -- Anacor,Pharmaceuticals, a privately held p... from its placebo-controlled Phase 1 trial of,AN27...gation for,the treatment of psoriasis. The trial s...omparable to existing topical,treatments for psori...
...k, June 06, 2007 /PRNewswire-FirstCall/,-- XTL Bio...ompleted the analysis of results from a Phase I cl...c Hepatitis C. This Phase I,trial was a placebo co... evaluated the safety, tolerability and antiviral ... The study enrolled 56,patients into seven cohorts...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
Inquire
...are is easy to configure for gravimetric calibrati...ndard method or enter your own parameters (number ... QualiTrace automatically manages the calibration ...from the balance to the software, which establishe...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile
Reagent Basin, 60mL, 5/Box
Medicine Products: